Potassium

Potassium

SCHEMBL9161975

CCCCCc1ccc(-c2ccc(C=CCC(P(=O)(O)O)S(=O)(=O)O)cc2)cc1.[K].[K].[K]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.44
S1PR1 P21453 8/20 0.43
S1PR3 Q99500 8/20 0.43
S1PR2 O95136 7/20 0.43
LPAR2 Q9HBW0 1/20 0.43
FDFT1 P37268 1/20 0.42
RARB P10826 5/20 0.40
S1PR4 O95977 5/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
RARA P10276 1/20 0.40
MAPT P10636 1/20 0.40
MTOR P42345 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
CASP3 P42574 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8618052 0.99 ENPP2 (0.45) ENPP2S1PR1S1PR3S1PR2LPAR2
SCHEMBL8618048 0.99 ENPP2 (0.45) ENPP2S1PR1S1PR3S1PR2LPAR2
SCHEMBL9161959 0.98 ENPP2 (0.44) ENPP2S1PR1S1PR3S1PR2LPAR2
SCHEMBL8619749 0.94 ENPP2 (0.50) ENPP2S1PR1S1PR3S1PR2LPAR2
SCHEMBL8619747 0.94 ENPP2 (0.50) ENPP2S1PR1S1PR3S1PR2LPAR2
SCHEMBL27416857 0.93 ENPP2 (0.49) ENPP2S1PR1S1PR3S1PR2LPAR2
SCHEMBL8623064 0.91 FDFT1 (0.38) ENPP2S1PR1S1PR3S1PR2LPAR2
SCHEMBL8623068 0.91 FDFT1 (0.38) ENPP2S1PR1S1PR3S1PR2LPAR2
SCHEMBL8625440 0.86 FDFT1 (0.40) ENPP2S1PR1S1PR3S1PR2LPAR2
SCHEMBL8625446 0.86 FDFT1 (0.40) ENPP2S1PR1S1PR3S1PR2LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US disclosed